Psychedelic drug

• 1. Chemical Families And Mechanisms

  ›

  In the brain, a single molecule of LSD binds to the serotonin 5-HT2A receptor and triggers a cascade that alters sensory perception. This interaction defines three primary chemical families: tryptamines, phenethylamines, and lysergamides. Tryptamines include psilocybin found in mushrooms and DMT found in plants like Psychotria viridis. Phenethylamines encompass mescaline derived from peyote cacti and synthetic compounds like 2C-B created by chemist Alexander Shulgin. Lysergamides feature LSD, synthesized by Albert Hofmann at Sandoz Laboratories in 1938. All three classes activate the same specific receptor but produce distinct subjective experiences. The intensity of hallucinogenic effects correlates directly with how tightly these molecules bind to the 5-HT2A receptor. Studies using positron emission tomography imaging confirm this relationship between binding affinity and human potency. Activation of this receptor modulates circuits involved in cognition and sensory processing within the medial prefrontal cortex. While the exact mechanism remains unknown, blocking this receptor with drugs like ketanserin abolishes the psychedelic state entirely. Some psychedelics also interact with other receptors such as 5-HT1A or dopamine systems, adding layers to their pharmacological profile.

• 2. Historical Discovery And Development

  ›

  Western science first encountered psychedelic substances through indigenous practices observed by explorers in the late nineteenth century. American physician John Raleigh Briggs published an article about peyote use in May 1887 after learning of it from Native Americans in Texas. German pharmacologist Louis Lewin obtained mescal buttons from Parke-Davis in June 1887 and began studying them shortly thereafter. Austrian chemist Ernst Späth achieved the first synthesis of pure mescaline in 1919, marking a turning point for pharmaceutical research. Swiss chemist Albert Hofmann synthesized LSD at Sandoz Laboratories in 1938 while developing oxytocic drugs derived from ergot fungus. He accidentally discovered its hallucinogenic properties when minute amounts absorbed through his skin during laboratory work. Three days later on April 19, Hofmann conducted a self-experiment that became known as Bicycle Day due to his bicycle ride home. Harvard psychologists Timothy Leary and Richard Alpert began studying LSD and psilocybin in the early 1960s before being fired from the university in 1963. The Wassons participated in a mushroom ceremony with Mazatec curandera Maria Sabina in Huautla de Jiménez, Oaxaca, Mexico in mid-1955. Gordon Wasson published his experience in Life magazine titled Seeking the Magic Mushroom in 1957, bringing global attention to traditional shamanic practices.

• 3. Cultural Impact And Prohibition

  ›

  Psychedelics became widely recreationally used by the public during the counterculture movement of the 1960s, particularly among hippies. English writer Aldous Huxley tried mescaline obtained from psychiatrist Humphry Osmond in 1953 and described its effects in his 1954 book The Doors of Perception. British politician Christopher Mayhew tried mescaline in 1955 and this was reported on in the media. Sandoz Laboratories ceased distribution of Delysid in 1965 after psychedelic clinical research throughout the world largely ceased by the end of the decade. Psychedelics became controlled substances in the United States and internationally in the 1960s and 1970s under UN conventions. The United States government conducted secret research into psychedelics as possible mind-control drugs through Project MKUltra by the Central Intelligence Agency. A 2013 survey found that 13.4% of American adults had used a psychedelic at some point in their lives. A June 2024 report by the RAND Corporation indicated that psilocybin mushrooms are currently the most widely used psychedelic drug among U.S. adults. Approximately 3% of respondents in a nationwide German survey published in 2025 had used LSD or related substances at least once in their lifetime. Despite legal barriers, recreational use continues to feature at festivals and events such as Burning Man.

• 4. Therapeutic Applications And Research

  ›

  Clinical trials explore the efficacy of psychedelic-assisted therapy for treating mental health disorders such as depression and addiction. As of 2021, psychedelic drugs remain controlled substances in most countries with therapy only legally available outside clinical trials. The United States Food and Drug Administration has granted breakthrough therapy status to psilocybin therapy for treatment-resistant depression. Ongoing research examines proposed therapies for conditions including major depressive disorder and anxiety linked to terminal illness. Studies using psilocybin in a psychotherapeutic setting reveal that these drugs may assist with treating alcohol addiction and nicotine addiction. A 2022 study recognized signatures of psilocybin microdosing in natural language suggesting potential application for ecological observation. More than 100 clinical trials of four major psychedelics were identified as being underway in 2024. Michael Pollan's 2018 book How to Change Your Mind increased mainstream awareness and interest in psychedelics significantly. The procedure differs from conventional psychiatric medications by administering the drug in a single session within a therapeutic context. Patients wear eyeshades and listen to music while the team provides reassurance if adverse effects like anxiety arise. Existing results suggest psychedelics could be effective treatments for certain mental health conditions despite needing further large-scale studies.

• 5. Safety Profiles And Adverse Effects

  ›

  Risks exist during unsupervised psychedelic experiences including fear, prolonged dread, or full panic according to Ira Byock writing in 2018. Driving or walking in public can be dangerous due to impaired hand-eye coordination and fine motor control during an experience. A 2023 international survey found 14% of respondents felt more anxious for an extended period following ingestion. In one survey, 9% of users reported functional impairment lasting at least 24 hours beyond the trip itself. One third of participants in a study of 608 people said difficulties lasted longer than a year, and one fifth said they lasted longer than three years. Most commonly-reported post-psychedelic difficulties included anxiety, feeling traumatized, social isolation, derealization, visual distortions, and existential confusion. Tolerance develops rapidly with repeated administration, showing almost complete absence of effects after 3 to 4 days of LSD use. Single high doses are widely thought safe but chronic microdosing may pose cardiac risks through serotonin 5-HT2B receptor activation. Fatal overdose cases have occurred with DMT, 5-MeO-DMT, 2C-B, and NBOMes though margins of safety vary significantly between compounds.